Business Wire

SIRION Biotech Licenses Adenovirus Technology to Danish Startup, InProTher for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)

MUNICH & COPENHAGEN, Denmark--(BUSINESS WIRE)--SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cell therapy, and InProTher Aps (“InProTher” ...
Forbes

Adenoviruses In Gene Therapy And Gene Editing

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine One of the more exciting opportunities in medical ...
The Conversation

Is it the adenovirus vaccine technology, used by AstraZeneca and Johnson & Johnson, causing blood clots? There’s no evidence yet

This week, US health authorities recommended pausing the rollout of the one-shot Johnson & Johnson/Janssen COVID-19 vaccine while investigations into exceptionally rare blood clots take place. Six ...
Seeking Alpha

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock ...

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer. BOSTON, March ...